Breaking News Instant updates and real-time market news.

VZ

Verizon

$54.96 /

+0.24 (+0.44%)

, BABA

Alibaba

$161.49 /

+4.11 (+2.61%)

07:46
09/13/18
09/13
07:46
09/13/18
07:46

Verizon in focus as former AOL chief Armstrong confirms exit

Tim Armstrong is leaving Oath, the Verizon (VZ) unit that encompasses both Yahoo and AOL, the company confirmed on Wednesday. He will be succeeded by Oath's chief operating officer K. Guru Gowrappan, who joined earlier this year from Alibaba (BABA). ARMSTRONG OUT: Tim Armstrong, the founder of Oath, is leaving the company at the end of the year, confirming reports last week that said Armstrong was in talks to depart. Armstrong came to Verizon in 2015 as part of the company's acquisition of AOL, where he had served as CEO. Verizon later acquired Yahoo and combined it with AOL into a new unit called Oath. Armstrong had attempted to build a digital advertising business to compete with Google (GOOG, GOOGL) and Facebook (FB), but the efforts so far have failed to generate much growth. According to a recent Wall Street Journal report, Verizon recently discussed whether to spin off the Oath business, but instead decided to integrate the unit more fully with the rest of the company's operations. Armstrong had pushed Verizon in recent months to better use its retail stores to promote Oath's services such as the ability to watch NFL football games on Yahoo Sports, sources said. GOWRAPPAN IN: K. Guru Gowrappan, who has been president and chief operating officer of Oath since April, will take over as CEO on October 1, with Armstrong remaining an adviser until the end of the year. "Guru has proven experience in scaling businesses globally. I'm thrilled he will lead Oath in an exciting new phase of growth, building on the foundation Tim and his team have created," Verizon CEO Hans Vestberg said in a statement." WHAT'S NOTABLE: This summer, Lowell McAdam stepped down as CEO of Verizon and was succeeded by Vestberg, the telecom company's chief technology officer and EVP and president of global networks. According to reports, by selecting Vestberg as CEO, Verizon's board signalled that it is continuing to focus on investments in wireless networks and technology, including building out a nationwide 5G broadband network, rather than media. PRICE ACTION: Verizon is fractionally lower in pre-market trading.

VZ

Verizon

$54.96 /

+0.24 (+0.44%)

BABA

Alibaba

$161.49 /

+4.11 (+2.61%)

GOOG

Alphabet

$1,162.64 /

-15.16 (-1.29%)

GOOGL

Alphabet Class A

$1,171.51 /

-18.13 (-1.52%)

FB

Ticker changed to META

$162.00 /

-3.96 (-2.39%)

  • 13

    Sep

  • 18

    Sep

  • 20

    Sep

  • 27

    Sep

  • 28

    Sep

  • 21

    Oct

  • 28

    Oct

OTHER BREAKING NEWS FROM THE FLY

Recommendations
Pacific Biosciences price target raised to $7.50 from $6 at Piper Sandler » 21:42
08/17/22
08/17
21:42
08/17/22
21:42
PACB

Pacific Biosciences

$7.60 /

-0.41 (-5.12%)

Piper Sandler analyst…

Piper Sandler analyst David Westenberg raised the firm's price target on Pacific Biosciences to $7.50 from $6 and keeps a Neutral rating on the shares. The analyst updated models in the genomic tools and labs space following earnings.

ShowHide Related Items >><<
PACB Pacific Biosciences
$7.60 /

-0.41 (-5.12%)

PACB Pacific Biosciences
$7.60 /

-0.41 (-5.12%)

08/11/22 Piper Sandler
Illumina miss 'surprising' given backlog, says Piper Sandler
08/04/22 Canaccord
Pacific Biosciences price target lowered to $14 from $17 at Canaccord
05/15/22 Piper Sandler
Pacific Biosciences price target lowered to $6 from $13 at Piper Sandler
05/05/22 Cantor Fitzgerald
Pacific Biosciences price target lowered to $19 from $23 at Cantor Fitzgerald
PACB Pacific Biosciences
$7.60 /

-0.41 (-5.12%)

PACB Pacific Biosciences
$7.60 /

-0.41 (-5.12%)

PACB Pacific Biosciences
$7.60 /

-0.41 (-5.12%)

Recommendations
OncoCyte price target raised to $1.50 from $1.40 at Piper Sandler » 21:42
08/17/22
08/17
21:42
08/17/22
21:42
OCX

OncoCyte

/

+

Piper Sandler analyst…

Piper Sandler analyst David Westenberg raised the firm's price target on OncoCyte to $1.50 from $1.40 and keeps an Overweight rating on the shares. The analyst updated models in the genomic tools and labs space following earnings.

ShowHide Related Items >><<
OCX OncoCyte
/

+

OCX OncoCyte
/

+

08/11/22 Lake Street
OncoCyte price target lowered to $3 from $6 at Lake Street
05/24/22 Stephens
Stephens downgrades OncoCyte to Equal Weight on limited near-term upside
05/24/22 Stephens
OncoCyte downgraded to Equal Weight from Overweight at Stephens
05/15/22 Piper Sandler
OncoCyte price target lowered to $1.40 from $1.80 at Piper Sandler
OCX OncoCyte
/

+

  • 14
    Apr
OCX OncoCyte
/

+

Recommendations
Invitae price target lowered to $2.25 from $2.50 at Piper Sandler » 21:42
08/17/22
08/17
21:42
08/17/22
21:42
NVTA

Invitae

$4.25 /

-0.2 (-4.50%)

Piper Sandler analyst…

Piper Sandler analyst David Westenberg lowered the firm's price target on Invitae to $2.25 from $2.50 and keeps an Underweight rating on the shares. The analyst updated models in the genomic tools and labs space following earnings.

ShowHide Related Items >><<
NVTA Invitae
$4.25 /

-0.2 (-4.50%)

NVTA Invitae
$4.25 /

-0.2 (-4.50%)

08/10/22 JPMorgan
Invitae cut to Underweight at JPMorgan with future growth yet to be proven
08/10/22 JPMorgan
Invitae downgraded to Underweight from Neutral at JPMorgan
07/26/22 Cowen
Invitae cut to Market Perform at Cowen on debt refinancing uncertainty
07/26/22 Cowen
Invitae downgraded to Market Perform from Outperform at Cowen
NVTA Invitae
$4.25 /

-0.2 (-4.50%)

NVTA Invitae
$4.25 /

-0.2 (-4.50%)

NVTA Invitae
$4.25 /

-0.2 (-4.50%)

Recommendations
Natera price target raised to $70 from $60 at Piper Sandler » 21:42
08/17/22
08/17
21:42
08/17/22
21:42
NTRA

Natera

$52.53 /

-2.595 (-4.71%)

Piper Sandler analyst…

Piper Sandler analyst David Westenberg raised the firm's price target on Natera to $70 from $60 and keeps an Overweight rating on the shares. The analyst updated models in the genomic tools and labs space following earnings.

ShowHide Related Items >><<
NTRA Natera
$52.53 /

-2.595 (-4.71%)

NTRA Natera
$52.53 /

-2.595 (-4.71%)

08/05/22 JPMorgan
Natera price target raised to $100 from $80 at JPMorgan
07/18/22 Piper Sandler
Natera CMS decision will drive more tests, says Piper Sandler
07/14/22 Piper Sandler
Piper says Natera selection for UnitedHealth network validates practices
05/15/22 Piper Sandler
Natera price target lowered to $60 from $75 at Piper Sandler
NTRA Natera
$52.53 /

-2.595 (-4.71%)

NTRA Natera
$52.53 /

-2.595 (-4.71%)

NTRA Natera
$52.53 /

-2.595 (-4.71%)

Recommendations
NeoGenomics price target raised to $19 from $13 at Piper Sandler » 21:41
08/17/22
08/17
21:41
08/17/22
21:41
NEO

NeoGenomics

$11.64 /

-0.45 (-3.72%)

Piper Sandler analyst…

Piper Sandler analyst David Westenberg raised the firm's price target on NeoGenomics to $19 from $13 and keeps an Overweight rating on the shares. The analyst updated models in the genomic tools and labs space following earnings.

ShowHide Related Items >><<
NEO NeoGenomics
$11.64 /

-0.45 (-3.72%)

NEO NeoGenomics
$11.64 /

-0.45 (-3.72%)

07/08/22 Piper Sandler
CMS proposal changes little for test companies, says Piper Sandler
06/02/22 Piper Sandler
NeoGenomics initiated with an Overweight at Piper Sandler
03/29/22 Cowen
NeoGenomics price target lowered to $24 from $42 at Cowen
03/29/22 BTIG
NeoGenomics price target lowered to $28 from $35 at BTIG
NEO NeoGenomics
$11.64 /

-0.45 (-3.72%)

NEO NeoGenomics
$11.64 /

-0.45 (-3.72%)

NEO NeoGenomics
$11.64 /

-0.45 (-3.72%)

Recommendations
Exact Sciences price target lowered to $40 from $50 at Piper Sandler » 21:41
08/17/22
08/17
21:41
08/17/22
21:41
EXAS

Exact Sciences

$39.56 /

-1.54 (-3.75%)

Piper Sandler analyst…

Piper Sandler analyst David Westenberg lowered the firm's price target on Exact Sciences to $40 from $50 and keeps an Overweight rating on the shares. The analyst updated models in the genomic tools and labs space following earnings.

ShowHide Related Items >><<
EXAS Exact Sciences
$39.56 /

-1.54 (-3.75%)

EXAS Exact Sciences
$39.56 /

-1.54 (-3.75%)

08/03/22 Craig-Hallum
Exact Sciences price target lowered to $60 from $81 at Craig-Hallum
08/03/22 Cowen
Exact Sciences price target lowered to $67 from $83 at Cowen
08/03/22 BTIG
Exact Sciences price target lowered to $70 from $100 at BTIG
08/03/22 Baird
Exact Sciences price target lowered to $75 from $90 at Baird
EXAS Exact Sciences
$39.56 /

-1.54 (-3.75%)

EXAS Exact Sciences
$39.56 /

-1.54 (-3.75%)

Recommendations
Cytek Biosciences price target raised to $16 from $12 at Piper Sandler » 21:41
08/17/22
08/17
21:41
08/17/22
21:41
CTKB

Cytek Biosciences

/

+

Piper Sandler analyst…

Piper Sandler analyst David Westenberg raised the firm's price target on Cytek Biosciences to $16 from $12 and keeps an Overweight rating on the shares. The analyst updated models in the genomic tools and labs space following earnings.

ShowHide Related Items >><<
CTKB Cytek Biosciences
/

+

CTKB Cytek Biosciences
/

+

08/17/22 Piper Sandler
Cytek Biosciences price target raised to $16 from $12 at Piper Sandler
07/19/22 Piper Sandler
Cytek Biosciences is best value in cell analysis, says Piper Sandler
06/22/22 Piper Sandler
Piper Sandler bullish on Cytek Biosciences following analyst day
05/15/22 Piper Sandler
Cytek Biosciences price target lowered to $12 from $17 at Piper Sandler
CTKB Cytek Biosciences
/

+

CTKB Cytek Biosciences
/

+

CTKB Cytek Biosciences
/

+

Recommendations
Cytek Biosciences price target raised to $16 from $12 at Piper Sandler » 21:41
08/17/22
08/17
21:41
08/17/22
21:41
CTKB

Cytek Biosciences

$14.09 /

-0.07 (-0.49%)

Piper Sandler analyst…

Piper Sandler analyst David Westenberg raised the firm's price target on Cytek Biosciences to $16 from $12 and keeps an Overweight rating on the shares. The analyst updated models in the genomic tools and labs space following earnings.

ShowHide Related Items >><<
CTKB Cytek Biosciences
$14.09 /

-0.07 (-0.49%)

CTKB Cytek Biosciences
$14.09 /

-0.07 (-0.49%)

07/19/22 Piper Sandler
Cytek Biosciences is best value in cell analysis, says Piper Sandler
06/22/22 Piper Sandler
Piper Sandler bullish on Cytek Biosciences following analyst day
05/15/22 Piper Sandler
Cytek Biosciences price target lowered to $12 from $17 at Piper Sandler
03/01/22 Piper Sandler
Cytek Biosciences price target lowered to $17 from $20 at Piper Sandler
CTKB Cytek Biosciences
$14.09 /

-0.07 (-0.49%)

CTKB Cytek Biosciences
$14.09 /

-0.07 (-0.49%)

CTKB Cytek Biosciences
$14.09 /

-0.07 (-0.49%)

Recommendations
Akoya Biosciences price target raised to $17 from $14 at Piper Sandler » 21:41
08/17/22
08/17
21:41
08/17/22
21:41
AKYA

Akoya Biosciences

$13.35 /

-0.64 (-4.57%)

Piper Sandler analyst…

Piper Sandler analyst David Westenberg raised the firm's price target on Akoya Biosciences to $17 from $14 and keeps an Overweight rating on the shares. The analyst updated models in the genomic tools and labs space following earnings.

ShowHide Related Items >><<
AKYA Akoya Biosciences
$13.35 /

-0.64 (-4.57%)

AKYA Akoya Biosciences
$13.35 /

-0.64 (-4.57%)

06/22/22 BTIG
Akoya Biosciences initiated with a Buy at BTIG
05/15/22 Piper Sandler
Akoya Biosciences price target lowered to $14 from $18 at Piper Sandler
04/13/22 Piper Sandler
Akoya not impacted from NanoString miss, says Piper Sandler
03/17/22 Piper Sandler
Akoya Biosciences price target lowered to $18 from $23 at Piper Sandler
AKYA Akoya Biosciences
$13.35 /

-0.64 (-4.57%)

Recommendations
Adaptive Biotechnologies price target raised to $12 from $7.50 at Piper Sandler » 21:40
08/17/22
08/17
21:40
08/17/22
21:40
ADPT

Adaptive Biotechnologies

$11.55 /

-0.345 (-2.90%)

Piper Sandler analyst…

Piper Sandler analyst David Westenberg raised the firm's price target on Adaptive Biotechnologies to $12 from $7.50 and keeps a Neutral rating on the shares. The analyst updated models in the genomic tools and labs space following earnings.

ShowHide Related Items >><<
ADPT Adaptive Biotechnologies
$11.55 /

-0.345 (-2.90%)

ADPT Adaptive Biotechnologies
$11.55 /

-0.345 (-2.90%)

06/02/22 Piper Sandler
Adaptive Biotechnologies initiated with a Neutral at Piper Sandler
02/16/22 BTIG
Adaptive Biotechnologies price target lowered to $30 from $35 at BTIG
02/02/22 BTIG
Adaptive Biotechnologies price target lowered to $35 from $45 at BTIG
01/11/22 BTIG
Adaptive Biotechnologies price target lowered to $45 from $55 at BTIG
ADPT Adaptive Biotechnologies
$11.55 /

-0.345 (-2.90%)

ADPT Adaptive Biotechnologies
$11.55 /

-0.345 (-2.90%)

Hot Stocks
Hyzon Motors names Parker Meeks as interim CEO » 21:03
08/17/22
08/17
21:03
08/17/22
21:03
HYZN

Hyzon Motors

$2.29 /

-0.065 (-2.77%)

Hyzon Motors…

Hyzon Motors "announced the company's Board of Directors has appointed Parker Meeks, most recently Hyzon's Chief Strategy Officer, as President and Interim CEO, effective immediately, replacing Craig Knight who is also departing from his role as a director of the Company. Mr. Meeks will assume full responsibility for day-to-day management of all business lines and functions reporting to the company's Board of Directors. The Board plans to initiate a search to identify potential external and internal candidates to serve as the Company's next CEO. Additionally, George Gu has transitioned from his executive role with the Company to the non-executive Chairman of the Board. In his role as non-executive Chairman, Mr. Gu will remain available to provide strategic counsel to Mr. Meeks specifically related to R&D initiatives."

ShowHide Related Items >><<
HYZN Hyzon Motors
$2.29 /

-0.065 (-2.77%)

HYZN Hyzon Motors
$2.29 /

-0.065 (-2.77%)

08/06/22 Goldman Sachs
Goldman Sachs suspends Hyzon Motors rating amid board investigation
08/05/22 DA Davidson
Hyzon Motors downgraded to Neutral from Buy at DA Davidson
08/05/22 Melius Research
Hyzon Motors downgraded to Hold from Buy at Melius Research
08/05/22 Wedbush
Hyzon Motors downgraded to Neutral from Outperform at Wedbush
HYZN Hyzon Motors
$2.29 /

-0.065 (-2.77%)

HYZN Hyzon Motors
$2.29 /

-0.065 (-2.77%)

Hot Stocks
SPDR Gold Shares holdings falls from 992.2MT to 989.0MT » 20:42
08/17/22
08/17
20:42
08/17/22
20:42
GLD

SPDR Gold Shares

$164.36 /

-1.08 (-0.65%)

This is the fourth…

This is the fourth consecutive decrease and the lowest level of holdings in seven months.

ShowHide Related Items >><<
GLD SPDR Gold Shares
$164.36 /

-1.08 (-0.65%)

GLD SPDR Gold Shares
$164.36 /

-1.08 (-0.65%)

Hot Stocks
Chewy CEO sells $11.26M in common stock » 20:31
08/17/22
08/17
20:31
08/17/22
20:31
CHWY

Chewy

$48.23 /

-1.825 (-3.65%)

In a regulatory filing,…

In a regulatory filing, Chewy disclosed that its CEO Sumit Singh sold 228.4K shares of common stock on August 15 in a total transaction size of $11.26M.

ShowHide Related Items >><<
CHWY Chewy
$48.23 /

-1.825 (-3.65%)

CHWY Chewy
$48.23 /

-1.825 (-3.65%)

08/04/22 Canaccord
Trupanion price target lowered to $90 from $100 at Canaccord
07/26/22 Wedbush
Wedbush downgrades Chewy to Neutral, raises price target to $44
07/26/22 Wedbush
Chewy downgraded to Neutral from Outperform at Wedbush
06/27/22 Needham
Chewy upgraded to Buy from Hold at Needham
CHWY Chewy
$48.23 /

-1.825 (-3.65%)

CHWY Chewy
$48.23 /

-1.825 (-3.65%)

CHWY Chewy
$48.23 /

-1.825 (-3.65%)

CHWY Chewy
$48.23 /

-1.825 (-3.65%)

Hot Stocks
Cathie Wood's ARK Investment bought 340K shares of Pacific Biosciences today  20:27
08/17/22
08/17
20:27
08/17/22
20:27
PACB

Pacific Biosciences

$7.60 /

-0.41 (-5.12%)

 
ShowHide Related Items >><<
PACB Pacific Biosciences
$7.60 /

-0.41 (-5.12%)

PACB Pacific Biosciences
$7.60 /

-0.41 (-5.12%)

08/11/22 Piper Sandler
Illumina miss 'surprising' given backlog, says Piper Sandler
08/04/22 Canaccord
Pacific Biosciences price target lowered to $14 from $17 at Canaccord
05/15/22 Piper Sandler
Pacific Biosciences price target lowered to $6 from $13 at Piper Sandler
05/05/22 Cantor Fitzgerald
Pacific Biosciences price target lowered to $19 from $23 at Cantor Fitzgerald
PACB Pacific Biosciences
$7.60 /

-0.41 (-5.12%)

PACB Pacific Biosciences
$7.60 /

-0.41 (-5.12%)

PACB Pacific Biosciences
$7.60 /

-0.41 (-5.12%)

Hot Stocks
Cathie Wood's ARK Investment bought 1.11M shares of Invitae today  20:26
08/17/22
08/17
20:26
08/17/22
20:26
NVTA

Invitae

$4.25 /

-0.2 (-4.50%)

 
ShowHide Related Items >><<
NVTA Invitae
$4.25 /

-0.2 (-4.50%)

NVTA Invitae
$4.25 /

-0.2 (-4.50%)

08/10/22 JPMorgan
Invitae cut to Underweight at JPMorgan with future growth yet to be proven
08/10/22 JPMorgan
Invitae downgraded to Underweight from Neutral at JPMorgan
07/26/22 Cowen
Invitae cut to Market Perform at Cowen on debt refinancing uncertainty
07/26/22 Cowen
Invitae downgraded to Market Perform from Outperform at Cowen
NVTA Invitae
$4.25 /

-0.2 (-4.50%)

NVTA Invitae
$4.25 /

-0.2 (-4.50%)

NVTA Invitae
$4.25 /

-0.2 (-4.50%)

Hot Stocks
Cathie Wood's ARK Investment bought 311K shares of Teladoc today  20:25
08/17/22
08/17
20:25
08/17/22
20:25
TDOC

Teladoc

$35.93 /

-3.51 (-8.90%)

 
ShowHide Related Items >><<
TDOC Teladoc
$35.93 /

-3.51 (-8.90%)

TDOC Teladoc
$35.93 /

-3.51 (-8.90%)

08/17/22 Guggenheim
Guggenheim cuts Teladoc to Sell with growth remaining pressured
08/17/22 Guggenheim
Teladoc downgraded to Sell from Neutral at Guggenheim
08/11/22 DA Davidson
Teladoc initiated with a Buy at DA Davidson
08/02/22 Berenberg
Berenberg downgrades Teladoc to Hold on 'underwhelming execution'
TDOC Teladoc
$35.93 /

-3.51 (-8.90%)

TDOC Teladoc
$35.93 /

-3.51 (-8.90%)

TDOC Teladoc
$35.93 /

-3.51 (-8.90%)

TDOC Teladoc
$35.93 /

-3.51 (-8.90%)

Earnings
Notable companies reporting before tomorrow's open » 20:25
08/17/22
08/17
20:25
08/17/22
20:25
EL

Estee Lauder

$276.80 /

+0.63 (+0.23%)

, BJ

BJ's Wholesale

$69.11 /

-0.125 (-0.18%)

, TPR

Tapestry

$37.12 /

-0.025 (-0.07%)

, KSS

Kohl's

$33.91 /

-1.165 (-3.32%)

Notable companies…

Notable companies reporting before tomorrow's open, with earnings consensus, include Estee Lauder (EL), consensus 33c... BJ's Wholesale (BJ), consensus 80c... Tapestry (TPR), consensus 77c... Kohl's (KSS), consensus $1.03.

ShowHide Related Items >><<
TPR Tapestry
$37.12 /

-0.025 (-0.07%)

KSS Kohl's
$33.91 /

-1.165 (-3.32%)

EL Estee Lauder
$276.80 /

+0.63 (+0.23%)

BJ BJ's Wholesale
$69.11 /

-0.125 (-0.18%)

EL Estee Lauder
$276.80 /

+0.63 (+0.23%)

08/09/22 Deutsche Bank
Estee Lauder price target lowered to $266 from $274 at Deutsche Bank
07/21/22 JPMorgan
Estee Lauder price target lowered to $265 from $270 at JPMorgan
05/31/22 Oppenheimer
Estee Lauder added back to Top Pick status at Oppenheimer
05/04/22 RBC Capital
Estee Lauder price target lowered to $322 from $361 at RBC Capital
BJ BJ's Wholesale
$69.11 /

-0.125 (-0.18%)

08/11/22 Deutsche Bank
BJ's Wholesale price target raised to $81 from $74 at Deutsche Bank
08/09/22 JPMorgan
BJ's Wholesale price target raised to $58 from $57 at JPMorgan
06/02/22 Jefferies
Costco price target raised to $580 from $560 at Jefferies
06/02/22 Jefferies
BJ's Wholesale price target raised to $72 from $69 at Jefferies
TPR Tapestry
$37.12 /

-0.025 (-0.07%)

07/21/22 BTIG
Tapestry price target lowered to $48 from $53 at BTIG
07/21/22 Goldman Sachs
Tapestry price target lowered to $35 from $39 at Goldman Sachs
07/15/22 UBS
Tapestry price target lowered to $31 from $36 at UBS
07/07/22 Wells Fargo
Tapestry price target lowered to $40 from $45 at Wells Fargo
KSS Kohl's
$33.91 /

-1.165 (-3.32%)

08/04/22 Cowen
Kohl's downgraded to Market Perform on consumer pressure at Cowen
08/04/22 Cowen
Kohl's downgraded to Market Perform from Outperform at Cowen
07/26/22 Deutsche Bank
Walmart outlook 'red flag for apparel,' says Deutsche Bank
07/15/22 UBS
Kohl's price target lowered to $20 from $32 at UBS
TPR Tapestry
$37.12 /

-0.025 (-0.07%)

KSS Kohl's
$33.91 /

-1.165 (-3.32%)

EL Estee Lauder
$276.80 /

+0.63 (+0.23%)

BJ BJ's Wholesale
$69.11 /

-0.125 (-0.18%)

KSS Kohl's
$33.91 /

-1.165 (-3.32%)

EL Estee Lauder
$276.80 /

+0.63 (+0.23%)

TPR Tapestry
$37.12 /

-0.025 (-0.07%)

KSS Kohl's
$33.91 /

-1.165 (-3.32%)

EL Estee Lauder
$276.80 /

+0.63 (+0.23%)

BJ BJ's Wholesale
$69.11 /

-0.125 (-0.18%)

TPR Tapestry
$37.12 /

-0.025 (-0.07%)

KSS Kohl's
$33.91 /

-1.165 (-3.32%)

EL Estee Lauder
$276.80 /

+0.63 (+0.23%)

BJ BJ's Wholesale
$69.11 /

-0.125 (-0.18%)

Downgrade
Stronghold Digital Mining downgraded to Market Perform from Outperform at Cowen » 20:17
08/17/22
08/17
20:17
08/17/22
20:17
SDIG

Stronghold Digital Mining

$2.39 /

-0.815 (-25.47%)

Cowen analyst Stephen…

Cowen analyst Stephen Glagola downgraded Stronghold Digital Mining to Market Perform from Outperform with a price target of $2.25, down from $11. The analyst cites the company's announced shift in the majority of its power generation to grid sales over the near term, downsizing to 1.4 EH/s amid a debt restructuring. Glagola warns that while this may be the best choice, the change also results in a sub-scale operator where management will have to establish credibility.

ShowHide Related Items >><<
SDIG Stronghold Digital Mining
$2.39 /

-0.815 (-25.47%)

SDIG Stronghold Digital Mining
$2.39 /

-0.815 (-25.47%)

08/17/22 B. Riley
Stronghold Digital Mining price target lowered to $4 from $5 at B. Riley
07/26/22 B. Riley
B. Riley adds Riot Blockchain to '25 for 2022' pick list, removes Stronghold
06/28/22 Compass Point
Stronghold Digital Mining price target lowered to $8 from $16 at Compass Point
06/23/22 B. Riley
Stronghold Digital Mining price target lowered to $5 from $13 at B. Riley
SDIG Stronghold Digital Mining
$2.39 /

-0.815 (-25.47%)

  • 20
    Oct
SDIG Stronghold Digital Mining
$2.39 /

-0.815 (-25.47%)

SDIG Stronghold Digital Mining
$2.39 /

-0.815 (-25.47%)

SDIG Stronghold Digital Mining
$2.39 /

-0.815 (-25.47%)

Hot Stocks
Newpark Resources director buys $239.5K in common stock » 19:03
08/17/22
08/17
19:03
08/17/22
19:03
NR

Newpark Resources

$2.64 /

-0.02 (-0.75%)

In a regulatory filing,…

In a regulatory filing, Newpark Resources disclosed that its director Donald Young bought 89.6K shares of common stock on August 15th in a total transaction size of $239.5K.

ShowHide Related Items >><<
NR Newpark Resources
$2.64 /

-0.02 (-0.75%)

Hot Stocks
CI&T acquires Transpire for A$16.4M » 19:01
08/17/22
08/17
19:01
08/17/22
19:01
CINT

CI&T

$13.90 /

+0.12 (+0.87%)

CI&T announced the…

CI&T announced the execution of a sale and purchase agreement to acquire Transpire Technology Pty Ltd, an Australian technology consultancy, to enhance its growth in APAC. The purchase price for the acquisition is A$23.4M, or $16.4M. Transpire recorded AUD15.5, or $10.9M, in net revenue in its fiscal year ended in June 2022. The completion of this transaction is subject to the satisfaction of customary closing conditions and is expected to happen during the third quarter of 2022.

ShowHide Related Items >><<
CINT CI&T
$13.90 /

+0.12 (+0.87%)

CINT CI&T
$13.90 /

+0.12 (+0.87%)

07/20/22 JPMorgan
CI&T price target lowered to $15 from $18 at JPMorgan
12/06/21
Fly Intel: Top five analyst initiations
12/06/21 BofA
BofA starts 'IT services rare breed' CI&T with a Buy
12/06/21 Morgan Stanley
Morgan Stanley starts CI&T at Overweight, sees shares trading at discount
CINT CI&T
$13.90 /

+0.12 (+0.87%)

  • 10
    Nov
CINT CI&T
$13.90 /

+0.12 (+0.87%)

CINT CI&T
$13.90 /

+0.12 (+0.87%)

Hot Stocks
NYSE to suspend trading in Eros Media World » 18:46
08/17/22
08/17
18:46
08/17/22
18:46
EMWP

Eros Media World

$1.61 /

-0.05 (-3.01%)

NYSE announced that the…

NYSE announced that the staff of NYSE Regulation has determined to commence proceedings to delist the A Ordinary Shares of Eros Media World Plc from the NYSE. Trading in the company's A Ordinary Shares will be suspended immediately. NYSE Regulation reached its decision that the company's A Ordinary Shares are not suitable for listing, because the company is a late filer and has not filed with the Securities and Exchange Commission its annual report on Form 20-F for the year ended March 31, 2021, current report on Form 6-K for the half year ended September 30, 2021 and annual report on Form 20-F for the year ended March 31, 2022. The company has a right to a review of this determination by a Committee of the Board of Directors of the Exchange.

Initiation
Casey's General Stores initiated with an Outperform at Wolfe Research » 18:30
08/17/22
08/17
18:30
08/17/22
18:30
CASY

Casey's General Stores

$212.86 /

-0.16 (-0.08%)

Wolfe Research analyst…

Wolfe Research analyst Greg Badishkanian initiated coverage of Casey's General Stores with an Outperform rating and $228 price target. The analyst cites the company being in the early innings of consolidating the industry with "underappreciated opportunities" to expand margins and grow its EBITDA by high single digits within a defensive category. At 11-times expected FY23 EBITDA, the risk-reward on the stock appears to be favorable, Badishkanian tells investors in a research note.

ShowHide Related Items >><<
CASY Casey's General Stores
$212.86 /

-0.16 (-0.08%)

CASY Casey's General Stores
$212.86 /

-0.16 (-0.08%)

07/18/22 Benchmark
Benchmark starts Casey's General Stores at Buy, cites proven growth model
07/18/22 Benchmark
Casey's General Stores initiated with a Buy at Benchmark
06/22/22 Deutsche Bank
Casey's General Stores price target lowered to $255 from $259 at Deutsche Bank
06/08/22 RBC Capital
Casey's General Stores price target lowered to $238 from $250 at RBC Capital
CASY Casey's General Stores
$212.86 /

-0.16 (-0.08%)

CASY Casey's General Stores
$212.86 /

-0.16 (-0.08%)

Periodicals
WWE board finds former CEO McMahon gave $5M to Trump charity, WSJ says » 18:25
08/17/22
08/17
18:25
08/17/22
18:25
WWE

WWE

$71.86 /

-1.41 (-1.92%)

An internal board…

An internal board investigation at World Wrestling Entertainment found that contributions totaling $5M to Donald Trump's charity in 2007 and 2009 were among the $19.6M in unrecorded expenses founder and former CEO Vince McMahon paid out before he left the company, the Wall Street Journal's Joe Palazzolo and Ted Man report. While the majority of the $19.6M in payments went to women who accused McMahon and another WWE executive of sexual misconduct, the company said previously in a regulatory filing that $5M was unrelated to such claims, the authors note. That particular amount represented charitable contributions to the now-dissolved Donald J. Trump Foundation in the same two years Trump made appearances at WWE televised events, the authors say, citing people familiar with the board investigation. Reference Link

ShowHide Related Items >><<
WWE WWE
$71.86 /

-1.41 (-1.92%)

WWE WWE
$71.86 /

-1.41 (-1.92%)

08/17/22 Benchmark
WWE price target raised to $83 from $80 at Benchmark
08/17/22 Barclays
Barclays ups WWE target but says company sale unlikely
07/26/22 Benchmark
WWE price target raised to $80 from $71 at Benchmark
07/25/22 Loop Capital
Loop Capital upgrades WWE to Buy on rising likelihood of company sale
WWE WWE
$71.86 /

-1.41 (-1.92%)

WWE WWE
$71.86 /

-1.41 (-1.92%)

WWE WWE
$71.86 /

-1.41 (-1.92%)

Earnings
America's Car-Mart reports Q1 EPS $2.00, consensus $3.14 » 18:20
08/17/22
08/17
18:20
08/17/22
18:20
CRMT

America's Car-Mart

$119.28 /

-6.68 (-5.30%)

Reports Q1 revenue…

Reports Q1 revenue $344.82M, consensus $322.4M. "For the quarter, unit sales volumes were up 2.1% to 15,536 with productivity (retail units sold per dealership per month) flat at 33.6, versus 1Q22. Even with significant industry headwinds, namely higher vehicles prices resulting from supply/demand imbalances, especially at lower price points, we saw unit volumes increase...," said CEO Jeff Williams. "Revenues were up 23% to $345M, our second highest revenue quarter in history, with 4Q22 being first. We are seeing car prices level off and we expect a gradual flattening as we move forward - better news for consumers. Overall industry credit results are normalizing, and we are seeing customers coming into our market as lending standards tighten above us. Net charge-offs as a percentage of average receivables, were 5.6% for the quarter, flat sequentially and up from 4.3% for the prior year quarter. The prior year quarter was positively affected by stimulus payments and the current quarter was negatively affected by inflationary factors," said Mr. Williams. "Net charge-off results for the quarter were in line with our prior 5-year average and below the prior 10-year average. Once again, inflation is presenting challenges; however, our customers are benefiting from a robust job market, helping to somewhat offset these pressures. As vehicle prices level off, affordability and resulting sales volume opportunities should improve."

ShowHide Related Items >><<
CRMT America's Car-Mart
$119.28 /

-6.68 (-5.30%)

CRMT America's Car-Mart
$119.28 /

-6.68 (-5.30%)

04/06/22 BofA
America's Car-Mart double-downgraded to Underperform at BofA
04/06/22 BofA
America's Car-Mart downgraded to Underperform from Buy at BofA
CRMT America's Car-Mart
$119.28 /

-6.68 (-5.30%)

CRMT America's Car-Mart
$119.28 /

-6.68 (-5.30%)

On The Fly
Fly Intel: After-Hours Movers » 18:16
08/17/22
08/17
18:16
08/17/22
18:16
WOLF

Wolfspeed

$85.58 /

-3.08 (-3.47%)

, CSCO

Cisco

$46.69 /

-0.09 (-0.19%)

, KEYS

Keysight Technologies

$169.27 /

-1.45 (-0.85%)

, SNPS

Synopsys

$380.78 /

-4.86 (-1.26%)

, BLUE

Bluebird Bio

$6.78 /

+0.195 (+2.96%)

, DCP

DCP Midstream

$34.75 /

-1.275 (-3.54%)

, BBWI

Bath & Body Works

$40.39 /

-0.63 (-1.54%)

, AXDX

Accelerate Diagnostics

$3.38 /

+0.165 (+5.14%)

, QUIK

QuickLogic

$7.64 /

-0.46 (-5.68%)

, BBBY

Bed Bath & Beyond

$22.98 /

+2.24 (+10.80%)

, GME

GameStop

$40.58 /

-1.57 (-3.72%)

, APRN

Blue Apron

$5.70 /

+0.315 (+5.85%)

, FUBO

FuboTV

$5.36 /

-1.005 (-15.80%)

, AMC

AMC Entertainment

$21.36 /

-3.45 (-13.91%)

ShowHide Related Items >><<
WOLF Wolfspeed
$85.58 /

-3.08 (-3.47%)

SNPS Synopsys
$380.78 /

-4.86 (-1.26%)

QUIK QuickLogic
$7.64 /

-0.46 (-5.68%)

KEYS Keysight Technologies
$169.27 /

-1.45 (-0.85%)

GME GameStop
$40.58 /

-1.57 (-3.72%)

FUBO FuboTV
$5.36 /

-1.005 (-15.80%)

DCP DCP Midstream
$34.75 /

-1.275 (-3.54%)

CSCO Cisco
$46.69 /

-0.09 (-0.19%)

BLUE Bluebird Bio
$6.78 /

+0.195 (+2.96%)

BBWI Bath & Body Works
$40.39 /

-0.63 (-1.54%)

BBBY Bed Bath & Beyond
$22.98 /

+2.24 (+10.80%)

AXDX Accelerate Diagnostics
$3.38 /

+0.165 (+5.14%)

APRN Blue Apron
$5.70 /

+0.315 (+5.85%)

AMC AMC Entertainment
$21.36 /

-3.45 (-13.91%)

WOLF Wolfspeed
$85.58 /

-3.08 (-3.47%)

08/15/22 Piper Sandler
ON Semiconductor price target raised to $90 from $75 at Piper Sandler
07/14/22 JPMorgan
Wolfspeed price target lowered to $80 from $105 at JPMorgan
06/29/22 BofA
Wolfspeed price target lowered to $75 from $95 at BofA
06/23/22 Goldman Sachs
Wolfspeed upgraded to Buy from Neutral at Goldman Sachs
CSCO Cisco
$46.69 /

-0.09 (-0.19%)

08/15/22 Citi
Cisco to trade lower due to valuation multiple compression, says Citi
08/02/22 Citi
Arista Networks price target raised to $170 from $160 at Citi
07/15/22 KGI Securities
Cisco downgraded to Neutral from Outperform at KGI Securities
07/14/22 JPMorgan
Cisco downgraded to Neutral from Overweight at JPMorgan
KEYS Keysight Technologies
$169.27 /

-1.45 (-0.85%)

08/09/22 Deutsche Bank
Keysight Technologies price target raised to $190 from $176 at Deutsche Bank
07/14/22 JPMorgan
Keysight Technologies price target lowered to $176 from $200 at JPMorgan
06/17/22 UBS
Keysight Technologies price target lowered to $177 from $220 at UBS
06/01/22 Goldman Sachs
Keysight Technologies price target lowered to $165 from $185 at Goldman Sachs
SNPS Synopsys
$380.78 /

-4.86 (-1.26%)

08/16/22 Wolfe Research
Synopsys initiated with an Outperform at Wolfe Research
08/11/22 Wells Fargo
Synopsys price target raised to $425 from $375 at Wells Fargo
06/29/22 BofA
Synopsys upgraded to Neutral from Underperform at BofA
05/19/22 Needham
Synopsys price target raised to $380 from $370 at Needham
BLUE Bluebird Bio
$6.78 /

+0.195 (+2.96%)

08/17/22 BTIG
Bluebird's approval has positive read for Mustang Bio, says BTIG
08/17/22 Piper Sandler
Piper says FDA nod for Bluebird's beta-cel positive for Crispr's exa-cel
08/05/22 Barclays
Barclays upgrades Bluebird Bio to Equal Weight, raises price target to $5
08/05/22 Barclays
Bluebird Bio upgraded to Equal Weight from Underweight at Barclays
DCP DCP Midstream
$34.75 /

-1.275 (-3.54%)

08/16/22 Barclays
DCP Midstream price target raised to $40 from $38 at Barclays
07/20/22 Barclays
DCP Midstream price target lowered to $38 from $43 at Barclays
07/12/22 RBC Capital
DCP Midstream upgraded to Outperform from Sector Perform at RBC Capital
06/13/22 Raymond James
DCP Midstream added to Analyst Current Favorites list at Raymond James
BBWI Bath & Body Works
$40.39 /

-0.63 (-1.54%)

08/16/22 B. Riley
Bath & Body Works price target raised to $48 from $44 at B. Riley
07/25/22 Barclays
Bath & Body Works price target lowered to $33 from $40 at Barclays
07/21/22 Deutsche Bank
Bath & Body Works price target lowered to $41 from $61 at Deutsche Bank
07/21/22 B. Riley
Bath & Body risk/reward attractive despite guidance cut, says B. Riley
AXDX Accelerate Diagnostics
$3.38 /

+0.165 (+5.14%)

03/09/22 Craig-Hallum
Craig-Hallum downgrades Accelerate Diagnostics to Hold, lowers target to $5
03/09/22 Craig-Hallum
Accelerate Diagnostics downgraded to Hold from Buy at Craig-Hallum
01/14/22 Craig-Hallum
Accelerate Diagnostics price target lowered to $9 from $12 at Craig-Hallum
QUIK QuickLogic
$7.64 /

-0.46 (-5.68%)

11/18/21 Roth Capital
QuickLogic price target raised to $12 from $8 at Roth Capital
BBBY Bed Bath & Beyond
$22.98 /

+2.24 (+10.80%)

08/16/22 Odeon Capital
Odeon Capital downgrades Bed Bath & Beyond to Sell with $7.50 price target
08/16/22 Odeon Capital
Bed Bath & Beyond downgraded to Sell from Hold at Odeon Capital
08/16/22 B. Riley
B. Riley downgrades 'meme stock' Bed Bath & Beyond to Sell
08/16/22 B. Riley
Bed Bath & Beyond downgraded to Sell from Neutral at B. Riley
GME GameStop
$40.58 /

-1.57 (-3.72%)

07/22/22 Wedbush
GameStop price target lowered to $7.50 from $30 at Wedbush
05/26/22 Wedbush
Wedbush keeps Underperform on GameStop citing valuation and cash burn concerns
03/28/22 B. Riley
Bed Bath & Beyond price target raised to $26 from $19 at B. Riley
APRN Blue Apron
$5.70 /

+0.315 (+5.85%)

08/10/22 Lake Street
Blue Apron initiated with a Buy at Lake Street
07/20/22 Benchmark
Benchmark starts Blue Apron at Buy with turnaround not getting credit
07/20/22 Benchmark
Blue Apron initiated with a Buy at Benchmark
05/10/22 Canaccord
Blue Apron price target lowered to $10 from $12 at Canaccord
FUBO FuboTV
$5.36 /

-1.005 (-15.80%)

08/17/22 Evercore ISI
FuboTV price target raised to $8 from $5 at Evercore ISI
08/17/22 Stephens
Stephens sees no major news from FuboTV analyst day to justify 'short squeeze'
08/17/22 Wedbush
Wedbush downgrades FuboTV to Neutral, raises price target to $6
08/17/22 Wedbush
FuboTV downgraded to Neutral from Outperform at Wedbush
AMC AMC Entertainment
$21.36 /

-3.45 (-13.91%)

07/07/22 Citi
AMC Entertainment price target lowered to $5 from $6 at Citi
06/21/22 B. Riley
AMC Entertainment price target lowered to $11 from $16 at B. Riley
06/06/22 Citi
AMC Entertainment shares remain overvalued, says Citi
WOLF Wolfspeed
$85.58 /

-3.08 (-3.47%)

SNPS Synopsys
$380.78 /

-4.86 (-1.26%)

QUIK QuickLogic
$7.64 /

-0.46 (-5.68%)

KEYS Keysight Technologies
$169.27 /

-1.45 (-0.85%)

GME GameStop
$40.58 /

-1.57 (-3.72%)

FUBO FuboTV
$5.36 /

-1.005 (-15.80%)

DCP DCP Midstream
$34.75 /

-1.275 (-3.54%)

CSCO Cisco
$46.69 /

-0.09 (-0.19%)

BLUE Bluebird Bio
$6.78 /

+0.195 (+2.96%)

BBWI Bath & Body Works
$40.39 /

-0.63 (-1.54%)

BBBY Bed Bath & Beyond
$22.98 /

+2.24 (+10.80%)

AXDX Accelerate Diagnostics
$3.38 /

+0.165 (+5.14%)

APRN Blue Apron
$5.70 /

+0.315 (+5.85%)

AMC AMC Entertainment
$21.36 /

-3.45 (-13.91%)

SNPS Synopsys
$380.78 /

-4.86 (-1.26%)

GME GameStop
$40.58 /

-1.57 (-3.72%)

CSCO Cisco
$46.69 /

-0.09 (-0.19%)

BLUE Bluebird Bio
$6.78 /

+0.195 (+2.96%)

BBBY Bed Bath & Beyond
$22.98 /

+2.24 (+10.80%)

APRN Blue Apron
$5.70 /

+0.315 (+5.85%)

AMC AMC Entertainment
$21.36 /

-3.45 (-13.91%)

WOLF Wolfspeed
$85.58 /

-3.08 (-3.47%)

SNPS Synopsys
$380.78 /

-4.86 (-1.26%)

QUIK QuickLogic
$7.64 /

-0.46 (-5.68%)

KEYS Keysight Technologies
$169.27 /

-1.45 (-0.85%)

GME GameStop
$40.58 /

-1.57 (-3.72%)

FUBO FuboTV
$5.36 /

-1.005 (-15.80%)

CSCO Cisco
$46.69 /

-0.09 (-0.19%)

BLUE Bluebird Bio
$6.78 /

+0.195 (+2.96%)

BBWI Bath & Body Works
$40.39 /

-0.63 (-1.54%)

BBBY Bed Bath & Beyond
$22.98 /

+2.24 (+10.80%)

APRN Blue Apron
$5.70 /

+0.315 (+5.85%)

AMC AMC Entertainment
$21.36 /

-3.45 (-13.91%)

WOLF Wolfspeed
$85.58 /

-3.08 (-3.47%)

SNPS Synopsys
$380.78 /

-4.86 (-1.26%)

GME GameStop
$40.58 /

-1.57 (-3.72%)

FUBO FuboTV
$5.36 /

-1.005 (-15.80%)

CSCO Cisco
$46.69 /

-0.09 (-0.19%)

BLUE Bluebird Bio
$6.78 /

+0.195 (+2.96%)

BBWI Bath & Body Works
$40.39 /

-0.63 (-1.54%)

BBBY Bed Bath & Beyond
$22.98 /

+2.24 (+10.80%)

APRN Blue Apron
$5.70 /

+0.315 (+5.85%)

AMC AMC Entertainment
$21.36 /

-3.45 (-13.91%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.